The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study.

ABSTRACT:

Introduction

Saxagliptin is a potent, reversible inhibitor of dipeptidyl peptidase-4 that is indicated for the treatment of type 2 diabetes. The DIAPAZON study was a multicenter observational study intended to document the effectiveness, safety and patterns of saxagliptin use in France, including the saxagliptin retention rate, over 2 years of follow-up.

Methods

A geographically representative sample of 304 French physicians (general practitioners and specialist endocrinologists or diabetologists) recruited 1131 adults with type 2 diabetes into an ambispective cohort; 1033 fulfilled the inclusion criteria. All had started saxagliptin during the previous 6 months or at study inclusion, and follow-up was for 24 ± 3 months after starting saxagliptin.

Results

The mean age

SUBMITTER: Balkau B 

PROVIDER: S-EPMC5630565 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature